Additionally, the expression of tumor-associated antigens such as MHC class I and class II molecules, as well as costimulatory CD80 and CD40, is also augmented by HDAC inhibition, so these tumors get more susceptible for immunotherapy [48]. Here, HDAC9 is linked to neoplasm.